PROK Stock Catalyst: ProKidney Corp. Reports Positive Phase 2 Trial Results for Rilparencel in CKD Patients

ProKidney Corp. announced on 2025-07-08 ProKidney reported statistically and clinically significant topline results from the Phase 2 REGEN-007 trial evaluating rilparencel in patients with chronic kidney disease (CKD) and diabetes.

The announcement cited 78%, -5.8 mL/min/1.73m 2, -1.3 mL/min/1.73m 2, 4.6 mL/min/1.73m 2, 50%, -3.4 mL/min/1.73m 2, -1.7 mL/min/1.73m 2, 1.7 mL/min/1.73m 2, 63%, 49, 69%, 22%, 33±10 mL/min/1.73m 2, 792 mg/g, 229 mg/g, 18 months, and 60 years.

PROKIDNEY CORP. has a free float of 93,274,000 shares and 141,545,000 shares outstanding.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.